Revenue GrowthRapid, sustained top-line expansion indicates clear product-market fit and successful commercial scaling. Accelerating revenue provides a runway to absorb fixed costs, enables operating leverage as sales grow, and supports a durable path to profitability if spending growth is controlled.

Very High Gross MarginExceptionally high and rising gross margins reflect strong unit economics and pricing power. Durable product-level profitability gives flexibility to invest in R&D and sales, cushions against input-cost shocks, and makes eventual operating leverage more achievable as revenue scales.

Conservative LeverageVery low leverage reduces financial risk and preserves strategic optionality while the business matures. A stronger equity cushion supports continued investment during loss-making growth phases and lowers bankruptcy risk versus highly leveraged peers.

Bears Say

Persistent Cash BurnOngoing negative operating and free cash flow require continual external financing, which can dilute shareholders and constrain strategic choices. Structural cash burn reduces runway and forces management to either slow growth or raise capital, limiting long-term independence.

Sustained Operating & Net LossesEven with strong revenue and margins, persistent operating and net losses mean the company hasn't translated product economics into overall profitability. This undermines retained-earnings funding for growth and necessitates a clear path to break-even to avoid structural value erosion.

Negative Return On EquityNegative ROE indicates the company is currently destroying shareholder value despite equity growth. If losses persist, the equity base may be pressured over time, necessitating improvement in operating profitability to preserve investor capital and justify continued funding.

OssDsign AB News

OssDsign’s Spine Registry Study: A Potential Game-Changer in Bone Graft Substitutes

OssDsign AB (($SE:OSSD)) announced an update on their ongoing clinical study. The OssDsign® Spine Registry Study, officially titled...

4M ago

OSSD

OSSD FAQ

What was OssDsign AB’s price range in the past 12 months?

OssDsign AB lowest stock price was kr5.70 and its highest was kr16.72 in the past 12 months.

What is OssDsign AB’s market cap?

OssDsign AB’s market cap is kr662.65M.

When is OssDsign AB’s upcoming earnings report date?

OssDsign AB’s upcoming earnings report date is May 20, 2026 which is in 76 days.

How were OssDsign AB’s earnings last quarter?

OssDsign AB released its earnings results on Feb 03, 2026. The company reported -kr0.2 earnings per share for the quarter, missing the consensus estimate of -kr0.17 by -kr0.03.

Is OssDsign AB overvalued?

According to Wall Street analysts OssDsign AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OssDsign AB pay dividends?

OssDsign AB does not currently pay dividends.

What is OssDsign AB’s EPS estimate?

OssDsign AB’s EPS estimate is -0.08.

How many shares outstanding does OssDsign AB have?

OssDsign AB has 110,625,916 shares outstanding.

What happened to OssDsign AB’s price movement after its last earnings report?

OssDsign AB reported an EPS of -kr0.2 in its last earnings report, missing expectations of -kr0.17. Following the earnings report the stock price went down -25.258%.

Which hedge fund is a major shareholder of OssDsign AB?

Currently, no hedge funds are holding shares in SE:OSSD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OssDsign AB

OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. The company's products include OSSDSIGN cranial, an implant solution and related accessories for skull defect reconstruction in cranioplasty patients; and OSSDSIGN facial to treat post-traumatic skeletal deformities and congenital skeletal defects. It also offers OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage; and OssDsign Catalyst, a nanosynthetic bone graft substitute that stimulates the formation of healthy bone tissue. The company was incorporated in 2011 and is headquartered in Uppsala, Sweden.